Saturn Oil + Gas, Bayer, Siemens Energy: Three companies for balance in volatile times

Saturn Oil & Gas focuses on growth and share buybacks

Canadian oil producer Saturn Oil & Gas is strengthening its commitment to further growth and share buybacks. This is evident from the latest live presentation at the 12th International Investment Forum on October 15, 2024.

Cindy Gray, VP Investor Relations, emphasizes: "A look at our fundamentals shows a current enterprise value of just over CAD 1.3 billion. Our outstanding shares will continue to decrease through our Normal Course Issuer Bid NCIB or share buyback program. This is part of our capital repatriation program initiated in August."

Management sees this as a cost-effective way to extend the life of reserves. A dividend strategy is not ruled out if the share price improves significantly and free cash flow increases substantially. However, this is not expected in the coming quarter.

Saturn has liquid assets of approximately CAD 120 million, providing a solid financial foundation. Saturn is also entitled to an unused credit line of CAD 150 million. Over the past four quarters, the Company has generated an adjusted EBITDA of nearly CAD 400 million.

Approximately 50% of free cash flow is to be used to reduce debt. Following the recent acquisition, Saturn anticipates a daily production of 38,000 to 40,000 boe/d (86% liquids). With more than 2,100 net wellbore locations identified, Saturn has significant development potential for the next 20 years. Saturn focuses on smaller acquisitions in existing areas to utilize existing infrastructure.

Bayer submits marketing authorization application for menopause drug to EMA

The Pharmaceuticals Division of Bayer AG has submitted a marketing authorization application to the European Medicines Agency (EMA) for the drug Elinzanetant. The drug is intended to treat moderate to severe vasomotor symptoms (VMS), also known as hot flashes.

This phenomenon occurs in the female body when the natural production of the hormone estrogen declines. The falling estrogen level leads to a dysregulation of body temperature in the hypothalamus, the temperature regulation center of the brain. If the hypothalamus erroneously perceives that the body temperature is too high, it sends the command to cool down the body. This is how the typical hot flash occurs, leading to the characteristic feeling of heat and redness of the skin - a harmless and, for some, unpleasant side effect of menopause. Christine Roth, Executive Vice President at Bayer, sees it differently and emphasizes the need for expanded treatment options for women during menopause.

The global market for menopause products and therapies is showing strong development. Experts predict growth to USD 26.97 billion by 2031, with a compound annual growth rate of 5.33% between 2024 and 2031.

Bayer has already submitted marketing authorization applications for Elinzanetant in Australia, Canada, Switzerland, the United Kingdom, and the United States, which have been accepted by the respective health authorities for review. The Company plans to submit further applications to health authorities worldwide. The Bayer share price rose 1.7% in the last three months and now stands at EUR 26.59.

Siemens Energy extends contract with CEO Bruch: Focus on wind business and offshore projects

The energy technology company Siemens Energy has extended the contract of its CEO Christian Bruch by five years until April 2030. Supervisory Board Chairman Joe Kaeser praised Bruch's performance during his first term of office, particularly the stabilization of the crisis-hit wind business.

Kaeser emphasized that the first positive effects of these measures are already visible. The targeted return of the wind business to profitability from 2026 will be one of the most extensive restructuring projects in Siemens' history.

According to Handelsblatt Siemens Energy is participating as a technology supplier in a major offshore wind energy project. The Company is equipping a transformer station for grid operator Amprion with the necessary technology. This converter platform is designed to collect electricity from offshore wind farms in the North Sea.

Despite a slight rise in the share price, the stock is still trading slightly below its 52-week high of EUR 36.62. However, it has recovered significantly from its 52-week low of EUR 6.40 and is currently trading at EUR 35.10.

Saturn Oil & Gas focuses on sustainable growth through share buybacks and smaller acquisitions. With solid finances and high development potential, the Company is focusing on debt reduction and efficient use of existing infrastructure. Bayer is expanding in the menopause medication market with Elinzanetant. The Company is exploiting the growth potential in this segment and is now also submitting marketing authorization applications in Europe. Siemens Energy is cementing its leadership by extending the contract of CEO Christian Bruch. The focus is on reorganizing the wind business and investing in offshore wind energy projects.